Your browser doesn't support javascript.
loading
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers.
Tinè, Mariaenrica; Pezzuto, Federica; Orlandi, Manuela; Caliò, Anna; Marletta, Stefano; Bondavalli, Tommaso; Giongo, Diego; Reghellin, Daniela; Posenato, Ilaria; Santacatterina, Maria; Menin, Andrea; Welte, Patrick Karl; Baciorri, Francesca; Sacchi, Diana; Catino, Cosimo; Nicolè, Lorenzo; Foltran, Gabriele; D'Urso, Alessandra; Orzes, Nicla; Andreotti, Giulia; Bartolotta, Patrizia; Gregori, Dario; Pasello, Giulia; Rea, Federico; Calabrese, Fiorella.
Afiliación
  • Tinè M; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Pezzuto F; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Orlandi M; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Caliò A; Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy.
  • Marletta S; Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy.
  • Bondavalli T; Respiratory Medicine Unit, Verona University Hospital, Verona, Italy.
  • Giongo D; Respiratory Medicine Unit, Verona University Hospital, Verona, Italy.
  • Reghellin D; Pathology Unit, "San Bortolo" Hospital, Vicenza, Italy.
  • Posenato I; Pathology Unit, "San Bortolo" Hospital, Vicenza, Italy.
  • Santacatterina M; Pathology Unit, "San Bortolo" Hospital, Vicenza, Italy.
  • Menin A; Pathology Unit, "San Bortolo" Hospital, Vicenza, Italy.
  • Welte PK; Respiratory Medicine Unit, "San Bortolo" Hospital, Vicenza, Italy.
  • Baciorri F; Pathology Unit, Ca' Foncello Hospital, Azienda Unità Locale Socio-Sanitaria 2 Marca Trevigiana, Treviso, Italy.
  • Sacchi D; Pathology Unit, Ca' Foncello Hospital, Azienda Unità Locale Socio-Sanitaria 2 Marca Trevigiana, Treviso, Italy.
  • Catino C; Pulmonology Unit, Ca' Foncello Hospital, Azienda Unità Locale Socio-Sanitaria 2 Marca Trevigiana, Treviso, Italy.
  • Nicolè L; Pathology Unit, Ospedale Dell'Angelo, Mestre, Italy.
  • Foltran G; UOC Pneumologia, Dipartimento Cardio-Toraco-vascolare, Ospedale dell'Angelo, Mestre, Italy.
  • D'Urso A; Pathology Unit, AULSS1 Dolomiti, Feltre, Italy.
  • Orzes N; Pulmonology Unit, AULSS1 Dolomiti, Feltre, Italy.
  • Andreotti G; UOC Pneumologia Cittadella, Euganea, Italy.
  • Bartolotta P; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Gregori D; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Pasello G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
  • Rea F; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Calabrese F; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Transl Lung Cancer Res ; 13(7): 1505-1517, 2024 Jul 30.
Article en En | MEDLINE | ID: mdl-39118890
ABSTRACT

Background:

Lung cancer is still the main cause of cancer death. In the last decades, significant innovations were introduced in non-small cell lung cancer (NSCLC) treatment and management improving patient outcomes. The discovery of immune checkpoint inhibitors and the detection of an increasing list of actionable genetic alterations are enabling a tailored approach. Herein, we assessed in a pragmatic retrospective study the rate of biomarker tests within a large pulmonary pathology-based unit (PPU) network of the Veneto region (Northern Italy).

Methods:

Each PPU of 7 hubs and spoke centers implemented a biomarker database with pathologic and clinical data of patients with NSCLC diagnosis over 24 months.

Results:

Out of 1,817 NSCLC cases, 51% were advanced and 49% early stage, with 72% being adenocarcinomas. Programmed death ligand 1 expression and epidermal growth factor receptor mutations were available in most samples, 91% and 78%, respectively. Only 36% of advanced stages received all 5 biomarker tests with an increased rate over time. Co-occurring molecular alterations were detected in 42 cases (2%) the prevalence was (n=17) 41% and (n=25) 59% in early and late-stage adenocarcinomas, respectively.

Conclusions:

In this real-world study, while most patients received at least one biomarker test, less than 50% had all 5 biomarkers. The screening appeared to increase over time especially with the progressive use of next generation sequencing. Our results confirm the importance of systematic biomarker testing including all NSCLCs based on the evidence of several genomic alterations also in early-stage disease whose analysis may become relevant as neo-adjuvant targeted therapies are available. Keywords Non-small cell lung cancer (NSCLC); biomarkers; actionable targets; lung cancer.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: China